Filing Details

Accession Number:
0001640455-21-000016
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-22 18:35:57
Reporting Period:
2021-01-20
Accepted Time:
2021-01-22 18:35:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1340881 C Kimberlee Drapkin C/o Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge MA 02139
Cfo And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-20 3,016 $0.48 58,897 No 4 M Direct
Common Stock Acquisiton 2021-01-20 6,775 $0.74 65,672 No 4 M Direct
Common Stock Acquisiton 2021-01-20 3,710 $2.36 69,382 No 4 M Direct
Common Stock Disposition 2021-01-20 16,201 $12.03 53,181 No 4 S Direct
Common Stock Disposition 2021-01-20 10,000 $10.03 43,181 No 4 S Direct
Common Stock Acquisiton 2021-01-21 3,799 $2.36 46,980 No 4 M Direct
Common Stock Disposition 2021-01-21 3,799 $12.00 43,181 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-01-20 3,016 $0.00 3,016 $0.48
Common Stock Stock Option (Right to Buy) Disposition 2021-01-20 6,775 $0.00 6,775 $0.74
Common Stock Stock Option (Right to Buy) Disposition 2021-01-20 3,710 $0.00 3,710 $2.36
Common Stock Stock Option (Right to Buy) Disposition 2021-01-21 3,799 $0.00 3,799 $2.36
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-01-27 No 4 M Direct
0 2025-01-12 No 4 M Direct
209,804 2025-08-25 No 4 M Direct
206,005 2025-08-25 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions.
  2. Represents the weighted average share price of an aggregate total of 16,201 shares sold in the price range of $12.00 to $12.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $10.00 to $10.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. Represents the weighted average share price of an aggregate total of 3,799 shares sold at $12.00 and $12.01 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. The option shares vested and became exercisable in 12 monthly installments from October 9, 2013.
  6. The option shares vested and became exercisable in 12 monthly installments from October 9, 2014.
  7. 25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.